Home
Resources
Follow portfolio news
...

Unlearn raises $50m to optimise clinical research using artificial intelligence

Published on
17/4/2024
Amended on
7/5/2026
0
minute(s)
Odyssey 2021
Cover Unlearn
Unlearn, a pioneering artificial intelligence company focused on creating digital twins* of clinical trial participants, has just announced another crucial milestone in its journey with a $50 million Series C funding round. Led by Altimeter Capital and with the participation of existing investors such as Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures and Necessary Venture Capital, this new round of funding propels Unlearn to new heights in its mission to radically transform clinical research through AI.
By
Damien Hélène
Damien Hélène
Unlearn raises $50m to optimise clinical research using artificial intelligence
This article has been automatically translated. Please excuse any inaccuracies or translation errors.
Dieser Artikel wurde automatisch übersetzt. Bitte entschuldigen Sie etwaige Ungenauigkeiten oder Übersetzungsfehler.
This article has been automatically translated. We apologize per inaccuracies or translation errors.

Since its inception in 2017, Unlearn has always been at the forefront of innovation, developing AI-based solutions to overcome major challenges in clinical research. With this latest round of funding, bringing the total amount raised to over $130 million, Unlearn is positioning itself to tackle key issues such as long timelines, slow participant recruitment and patient reluctance to join clinical trials for fear of receiving a placebo.

The revolutionary approach of Unlearn, a company present in the Vintage Altaroc Odyssey 2021, is based on the creation of personalized digital twins for each participant in a clinical trial, predicting their health outcomes under placebo, independently of their actual assignment. This technology makes it possible to set up TwinRCTs (TM), highly powerful clinical trials with smaller control groups, giving a greater number of patients the opportunity to benefit from experimental treatments.

By reducing the time it takes to bring new drugs and therapies to market, Unlearn paves the way for significant improvements in healthcare outcomes for all.

Dr. Charles Fisher, founder and CEO of Unlearn, emphasizes the importance of this new round of funding in pursuing the company's mission: "We are determined to overcome the obstacles and prove the value of digital twin technology. This new injection of capital will enable us not only to strengthen our team, but also to extend our capabilities to other therapeutic areas, while raising awareness of the importance of our work."

In recent years, the clinical research industry has seen the emergence of advanced solutions to its most pressing challenges. However, regulatory constraints have often impeded progress. Unlearn has successfully navigated this complex landscape by partnering with regulatory experts and gaining important qualifications, notably from the European Medicines Agency and the US Food and Drug Administration.

The company is also collaborating with biotech companies and academic institutions to accelerate the evaluation process for new treatments, paving the way for a new era of medical discovery.

*The digital twin is not a robot or a 3D body reproduction, but a data set that mirrors each human organism as closely as possible.

Other episodes on this topic

Explore our content collections, which bring together different formats around a single subject/issue/theme.
No articles in this category yet.
Welcome to Altaroc
To provide you with a tailored experience, please complete your profile.
Please fill out your profile to access the site
country of tax residence
Select
choosenCountry
Preferred language
Select
choosenLang
YOUR INVESTOR PROFILE
Financial intermediary or professional investor
Financial advisors, wealth managers, private bankers, or any other investment service providers.
Qualified Investor or Altaroc Investor
Experienced investor or Altaroc investor
Private investors who have already invested with Altaroc or who have a minimum investment capacity of €100,000.
Private investors who have previously invested in Altaroc who have a minimum investment capacity of 200,000 euros.
Non-professional (retail) investor
Individual investors with an investment capacity below €100,000.
Retail investors with an investment capacity of less than 200,000 euros.
Institutional investor
Pension funds, retirement schemes, asset management companies, and single-family offices.
Select your language and investor profile to continue
Select your investor profile to continue
Scroll down to accept General Terms and Conditions
The webpage you are trying to access is not available in your country.